Skip to main content
. 2022 Apr 1;40(20):2235–2245. doi: 10.1200/JCO.21.02840

FIG 2.

FIG 2.

Diagnoses and actionable MAPK pathway mutations of arm E patients. (A) Pie chart of the histologic diagnoses of the 58 matched patients. (B) Pie chart of the histologic diagnoses of the 20 treated patients. (C) Pie chart of the types of actionable MAPK pathway tumor alterations detected in the 58 matched patients (n = 60 mutations). (D) Pie chart of the types of actionable MAPK pathway tumor alterations detected in the 20 treated patients (n = 21 mutations). (E) Tumor variants detected by gene and patient. The genes with variants are indicated for each patient (each column represents a patient). The 20 patients treated in arm E are on the left side of the figure; the remainder of the matched patients are on the right. The histogram on the left gives the number of variants detected for each alteration type. Actionable MAPK pathway alterations are in the top rows of the figure (KRAS mutation to BRAF other); other cancer gene alterations identified by the tumor panel testing are listed in the rows below. HGG, high-grade glioma; LGG, low-grade glioma; MAPK, mitogen-activated protein kinase; Mut, mutation; RMS, rhabdomyosarcoma.